We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug Resistant Bacterial Strains Impact Infectious Disease Diagnostic Segment

By LabMedica International staff writers
Posted on 02 Sep 2009
The most substantial growth in the US $8.4 billion market for infectious disease diagnostics will be in molecular testing. More...
The expanding population of drug resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and multidrug resistant Mycobacterium tuberculosis (TB) will vindicate the use of nucleic acid-based tests (NAT).

The two traditional methods, culture-based assays and immunoassays, are becoming increasingly inadequate for infectious disease testing. Emergence of drug-resistant bacterial strains means that immunoassays have no analytical potential. Culture-based assays for bacterial susceptibility/sensitivity, although inexpensive, are slow and often difficult.

Laboratories are still largely equipped with immunoassay instrumentation, but not all have access to a thermal cycler or the expertise to perform a molecular MRSA test. According to a report by life science market research company Kalorama Information, (New York, NY, USA) replacement of current assays with molecular-based tests will be slow because of the recession. Therefore, both culture-based assays and immunoassays will remain in use for infectious disease tests that do not require rapid turn-around or are otherwise difficult to perform. The cost of nuclear acid-based NAT assays, which are not usually analyzed outside the hospital laboratory, is high at around $25-$35, while selective media cost about $5 a plate.

"Relevancy is established through significantly improved efficacy and not marginal improvement,” said Bruce Carlson, publisher of Kalorama Information. "NAT testing can be put to many uses, but what will get it into more labs is its role in determining the genetic differences that make a bacterial strain […..] drug resistant, with results in 2-4 hours.”

NAT testing will allow physicians to rapidly select combination therapeutics for infections caused by resistant organisms. In viral applications, for example in human immunodeficiency virus (HIV) infection, NAT testing successfully detected drug resistance that developed in response to therapy.

Related Links:
Kalorama Information


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.